Lipocine Inc. (LPCN)
LPCN moved a median of +0.34% 30 minutes after news, and +0.40% by the close. How LPCN actually reacts to news — the realized, point-in-time move the market made, measured across 219 labeled events over the last three years with zero look-ahead.
LPCN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 182 |
| 30-min | +0.34% | 52% | 205 |
| 60-min | +0.16% | 51% | 217 |
| to close | +0.40% | 51% | 217 |
| Middle 50% of LPCN reactions | -1.27% to +2.22% |
|---|---|
| Median reaction (30-min) | +0.34% |
| Measured reactions | 219 |
Half of all Lipocine Inc. news events land between -1.27% and +2.22% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LPCN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 54 | 0.00% | 44% | -0.84% |
| Rating reiterations | 14 | -0.05% | 50% | +0.92% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how LPCN ranks against every other measured name →
That’s how LPCN usually reacts — get an email when it moves on news →Email me when LPCN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LPCN's baseline. Nothing else.
Recent LPCN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Lipocine Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -6.12% | -24.66% | |
| Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy | Press release | PR Newswire | -6.12% | -24.66% | |
| Form 8-K Lipocine Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.78% | |
| Form 8-K Lipocine Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.91% | |
| Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression | Press release | PR Newswire | +0.00% | +0.91% | |
| Form 8-K Lipocine Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Form 8-K Lipocine Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | — | -2.60% | |
| Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | — | -2.60% | |
| Form 8-K/A Lipocine Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.48% | |
| Form 10-Q Lipocine Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.17% | +0.00% | |
| Form 8-K Lipocine Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +1.17% | +0.00% | |
| Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 | Press release | PR Newswire | +1.17% | +0.00% | |
| Form 8-K Lipocine Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -5.76% | -5.76% | |
| Lipocine Appoints Michael J. Grissinger to Board of Directors | Press release | PR Newswire | +4.63% | -1.40% | |
| Form 8-K Lipocine Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.33% | |
| Form S-8 Lipocine Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.99% | -1.49% | |
| Form 8-K Lipocine Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | -6.82% | |
| Form 8-K Lipocine Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.94% | +3.27% | |
| Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 | Press release | PR Newswire | +0.94% | +3.27% | |
| Form 8-K Lipocine Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -3.40% | -2.98% | |
| Form 8-K Lipocine Inc. For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.93% | |
| Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting | Press release | PR Newswire | +0.00% | -3.93% | |
| Form 8-K Lipocine Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | -2.21% | |
| Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase | Press release | PR Newswire | +0.30% | -2.21% | |
| Form 10-Q Lipocine Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.42% | |
| Form 8-K Lipocine Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.42% | |
| Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | Press release | PR Newswire | +2.49% | -1.66% | |
| Form 8-K Lipocine Inc. For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +3.42% | |
| Form DEF 14A Lipocine Inc. For: Apr 21 | SEC filing · Form DEF | SEC EDGAR | -0.43% | +3.42% | |
| Form DEFA14A Lipocine Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.43% | +3.42% | |
| Form 8-K Lipocine Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | -1.44% | |
| Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression | Press release | PR Newswire | +3.48% | +1.99% | |
| Form 10-K Lipocine Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.47% | +2.01% | |
| Form 8-K Lipocine Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +5.47% | +2.01% | |
| Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 | Press release | PR Newswire | +5.47% | +2.01% | |
| Form 8-K Lipocine Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -1.90% | -2.62% | |
| Form 8-K Lipocine Inc. For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | -4.21% | |
| Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) | Press release | PR Newswire | +2.85% | -1.48% | |
| Form 8-K Lipocine Inc. For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -0.71% | -8.37% | |
| Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | Press release | PR Newswire | -0.27% | -8.99% | |
| Form 8-K Lipocine Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +12.72% | |
| Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | Press release | PR Newswire | -0.10% | +12.59% | |
| Form 8-K Lipocine Inc. For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +0.32% | |
| Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Press release | PR Newswire | +1.29% | +1.29% | |
| Form 8-K Lipocine Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | +1.29% | |
| Form 8-K Lipocine Inc. For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | +0.64% | |
| Form 8-K Lipocine Inc. For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +6.35% | +7.30% | |
| Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | Press release | PR Newswire | +7.42% | +9.03% | |
| Form 10-Q Lipocine Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.75% | -1.49% | |
| Form 8-K Lipocine Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | -1.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LPCN section they belong to.
Where else LPCN is measured.
LPCN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PROVECTUS BIOPHARMS (PVCT) | 220 | +0.01% | 50% |
| TG Therapeutics, Inc. (TGTX) | 220 | -0.06% | 47% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
| AngioDynamics, Inc. (ANGO) | 218 | +0.33% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Lipocine Inc.'s median reaction calculated?
Every labeled LPCN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 219 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of LPCN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LPCN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.